Restasis vs Tepezza
A side-by-side look at two eye health medications advertised on TV. Informational only — not medical advice.
| US Restasis | US Tepezza | |
|---|---|---|
| Generic name | cyclosporine ophthalmic emulsion | teprotumumab |
| Drug class | Calcineurin Inhibitor (Eye Drop) | IGF-1R Inhibitor (Biologic) |
| Treats | Chronic dry eye | Thyroid eye disease |
| Category | Eye Health | Eye Health |
| Manufacturer | AbbVie (Allergan) | Amgen |
| Year approved | 2003 | 2020 |
| FDA warning | No boxed warning | Moderate warnings |
| Est. TV ad spend | $100M | — |
| Common side effects | Burning sensation, Eye redness, Watery eyes, Blurred vision | Muscle spasms, Nausea, Hair loss, Hearing problems |
Frequently asked questions
Is Restasis or Tepezza better?
Neither is universally "better." Restasis (cyclosporine ophthalmic emulsion) and Tepezza (teprotumumab) are both used for eye health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Restasis and Tepezza?
Restasis is a Calcineurin Inhibitor (Eye Drop) made by AbbVie (Allergan), while Tepezza is a IGF-1R Inhibitor (Biologic) made by Amgen. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Restasis has the larger estimated TV advertising budget of the two.